We read with great interest the recently published American College of Rheumatology guideline for the treatment of patients with rheumatoid arthritis (RA) (1). Among the various issues covered is the hypogammaglobulinemia that occasionally occurs in rituximab-treated RA patients. Hypogammaglobulinemia has been reported in about 17-43% of these patients (2). Risk factors for its occurrence are ill-defined, however the number of rituximab cycles and the baseline levels of immunoglobulins are the most described (2-7).

中文翻译：

---

用利妥昔单抗治疗的类风湿关节炎患者的低丙种球蛋白血症：我们应该换用生物制剂吗？评论 Fraenkel 等人的文章 (DOI: 10.1002/art.41752)

我们怀着极大的兴趣阅读了美国风湿病学会最近发布的类风湿关节炎 (RA) 患者治疗指南 (1)。涵盖的各种问题包括在利妥昔单抗治疗的 RA 患者中偶尔发生的低丙种球蛋白血症。据报道，这些患者中约有 17-43% 患有低丙种球蛋白血症 (2)。其发生的风险因素不明确，但描述最多的是利妥昔单抗周期数和免疫球蛋白基线水平 (2-7)。